publication date: Feb. 28, 2020
Issue 9 - Feb. 28, 2020
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.
  • ODAC: Thumbs up for Eli Lilly’s Cyramza, thumbs down for STEBA’s Tookad

    The FDA Oncologic Drugs Advisory Committee Feb. 26 voted down a vascular-targeted photodynamic therapy for early-stage, low-risk prostate cancer and, in a narrow vote, recommended approval for a combination of a VEGF receptor 2 antagonist and an EGFR-targeting tyrosine kinase inhibitor for front-line treatment of EGFR-positive non-small cell lung cancer.

  • FDA approved 11 new agents, 30 supplemental indications in cancer in 2019

    Last year, FDA approved 11 new drugs and biologics as well as 30 supplemental indications and four biosimilars, according to commentary by FDA officials published in Nature Reviews.

  • In Brief

    • Jennifer Cullen named associate director of Cancer Population Sciences at Case CCC
    • Aaron Gerds named medical director of Clinical Research Office at Case CCC
    • Cantley, Bernstein, Pui receive Medal of Honor award from ACS


  • TCCL Logo

  • Clinical Roundup

    • Immunotherapy combination effective for patients with high-grade neuroendocrine cancer
    • Definitions of malnutrition apply differently depending on cancer type
  • Drugs & Targets

    • FDA approves neratinib for metastatic HER2-positive breast cancer
    • FDA accepts sNDA for Zejula in ovarian cancer indication
    • FDA grants RMAT designation to CD30 CAR-T Cell Therapy in hodgkin lymphoma indication
    • PMC report: FDA addressed rare diseases, expanded cancer treatment and targeted therapies in 2019
    • Boehringer Ingelheim and Trutino Biosciences collaborate to grow cancer immunology portfolio with novel cytokine platform

Copyright (c) 2020 The Cancer Letter Inc.